Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer's disease.

Hartlage-Rübsamen M, Ratz V, Zeitschel U, Finzel L, Machner L, Köppen J, Schulze A, Demuth HU, von Hörsten S, Höfling C, Roßner S.

Acta Neuropathol Commun. 2019 May 20;7(1):79. doi: 10.1186/s40478-019-0726-2.

2.

Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of Aβ with Glutaminyl Cyclase-Catalyzed pGlu-Aβ Formation.

Schlenzig D, Cynis H, Hartlage-Rübsamen M, Zeitschel U, Menge K, Fothe A, Ramsbeck D, Spahn C, Wermann M, Roßner S, Buchholz M, Schilling S, Demuth HU.

J Alzheimers Dis. 2018;66(1):359-375. doi: 10.3233/JAD-171183.

PMID:
30320570
3.

Continuous assays for meprin alpha and beta using prolyl tripeptidyl aminopeptidase (PtP) from Porphyromonas gingivalis.

Schulze A, Wermann M, Demuth HU, Yoshimoto T, Ramsbeck D, Schlenzig D, Schilling S.

Anal Biochem. 2018 Oct 15;559:11-16. doi: 10.1016/j.ab.2018.08.005. Epub 2018 Aug 9.

PMID:
30098994
4.

Kallikrein-related peptidases are activators of the CC chemokine CCL14.

Grünberg M, Quandt D, Cynis H, Demuth HU, Kindermann A, Magdolen V, Forssmann WG, Seliger B, Mägert HJ.

Eur J Immunol. 2018 Sep;48(9):1592-1594. doi: 10.1002/eji.201747452. Epub 2018 Aug 22.

5.

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.

Hartlage-Rübsamen M, Bluhm A, Piechotta A, Linnert M, Rahfeld JU, Demuth HU, Lues I, Kuhn PH, Lichtenthaler SF, Roßner S, Höfling C.

Molecules. 2018 Apr 17;23(4). pii: E924. doi: 10.3390/molecules23040924.

6.

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.

Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.

J Alzheimers Dis. 2018;63(1):115-130. doi: 10.3233/JAD-170775.

7.

Aβ oligomer eliminating compounds interfere successfully with pEAβ(3-42) induced motor neurodegenerative phenotype in transgenic mice.

Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen KJ, Demuth HU, Shah NJ, Kutzsche J, Willuweit A, Willbold D.

Neuropeptides. 2018 Feb;67:27-35. doi: 10.1016/j.npep.2017.11.011. Epub 2017 Nov 27.

PMID:
29273382
8.

Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro.

Antonyan A, Schlenzig D, Schilling S, Naumann M, Sharoyan S, Mardanyan S, Demuth HU.

Neurochem Int. 2018 Feb;113:112-119. doi: 10.1016/j.neuint.2017.12.001. Epub 2017 Dec 7.

PMID:
29224965
9.

N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.

Kehlen A, Haegele M, Böhme L, Cynis H, Hoffmann T, Demuth HU.

Biosci Rep. 2017 Aug 23;37(4). pii: BSR20170712. doi: 10.1042/BSR20170712. Print 2017 Aug 31.

10.

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.

Piechotta A, Parthier C, Kleinschmidt M, Gnoth K, Pillot T, Lues I, Demuth HU, Schilling S, Rahfeld JU, Stubbs MT.

J Biol Chem. 2017 Jul 28;292(30):12713-12724. doi: 10.1074/jbc.M117.777839. Epub 2017 Jun 16.

11.

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.

Hoffmann T, Meyer A, Heiser U, Kurat S, Böhme L, Kleinschmidt M, Bühring KU, Hutter-Paier B, Farcher M, Demuth HU, Lues I, Schilling S.

J Pharmacol Exp Ther. 2017 Jul;362(1):119-130. doi: 10.1124/jpet.117.240614. Epub 2017 Apr 26.

PMID:
28446518
12.

Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.

Grochowska KM, Yuanxiang P, Bär J, Raman R, Brugal G, Sahu G, Schweizer M, Bikbaev A, Schilling S, Demuth HU, Kreutz MR.

EMBO Rep. 2017 Jun;18(6):962-981. doi: 10.15252/embr.201643519. Epub 2017 Apr 18.

13.

Recent progress in translational research on neurovascular and neurodegenerative disorders.

Demuth HU, Dijkhuizen RM, Farr TD, Gelderblom M, Horsburgh K, Iadecola C, Mcleod DD, Michalski D, Murphy TH, Orbe J, Otte WM, Petzold GC, Plesnila N, Reiser G, Reymann KG, Rueger MA, Saur D, Savitz SI, Schilling S, Spratt NJ, Turner RJ, Vemuganti R, Vivien D, Yepes M, Zille M, Boltze J; ISN&N meeting contributors.

Restor Neurol Neurosci. 2017;35(1):87-103. doi: 10.3233/RNN-160690. Review.

14.

Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.

Hielscher-Michael S, Griehl C, Buchholz M, Demuth HU, Arnold N, Wessjohann LA.

Mar Drugs. 2016 Nov 2;14(11). pii: E203.

15.

Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.

Hellvard A, Zeitlmann L, Heiser U, Kehlen A, Niestroj A, Demuth HU, Koziel J, Delaleu N, Jan Potempa, Mydel P.

Sci Rep. 2016 Aug 11;6:31441. doi: 10.1038/srep31441.

16.

11th German Conference on Chemoinformatics (GCC 2015) : Fulda, Germany. 8-10 November 2015.

Fechner U, de Graaf C, Torda AE, Güssregen S, Evers A, Matter H, Hessler G, Richmond NJ, Schmidtke P, Segler MHS, Waller MP, Pleik S, Shea JE, Levine Z, Mullen R, van den Broek K, Epple M, Kuhn H, Truszkowski A, Zielesny A, Fraaije JH, Gracia RS, Kast SM, Bulusu KC, Bender A, Yosipof A, Nahum O, Senderowitz H, Krotzky T, Schulz R, Wolber G, Bietz S, Rarey M, Zimmermann MO, Lange A, Ruff M, Heidrich J, Onlia I, Exner TE, Boeckler FM, Bermudez M, Firaha DS, Hollóczki O, Kirchner B, Tautermann CS, Volkamer A, Eid S, Turk S, Rippmann F, Fulle S, Saleh N, Saladino G, Gervasio FL, Haensele E, Banting L, Whitley DC, Oliveira Santos JS, Bureau R, Clark T, Sandmann A, Lanig H, Kibies P, Heil J, Hoffgaard F, Frach R, Engel J, Smith S, Basu D, Rauh D, Kohlbacher O, Boeckler FM, Essex JW, Bodnarchuk MS, Ross GA, Finkelmann AR, Göller AH, Schneider G, Husch T, Schütter C, Balducci A, Korth M, Ntie-Kang F, Günther S, Sippl W, Mbaze LM, Ntie-Kang F, Simoben CV, Lifongo LL, Ntie-Kang F, Judson P, Barilla J, Lokajíček MV, Pisaková H, Simr P, Kireeva N, Petrov A, Ostroumov D, Solovev VP, Pervov VS, Friedrich NO, Sommer K, Rarey M, Kirchmair J, Proschak E, Weber J, Moser D, Kalinowski L, Achenbach J, Mackey M, Cheeseright T, Renner G, Renner G, Schmidt TC, Schram J, Egelkraut-Holtus M, van Oeyen A, Kalliokoski T, Fourches D, Ibezim A, Mbah CJ, Adikwu UM, Nwodo NJ, Steudle A, Masek BB, Nagy S, Baker D, Soltanshahi F, Dorfman R, Dubrucq K, Patel H, Koch O, Mrugalla F, Kast SM, Ain QU, Fuchs JE, Owen RM, Omoto K, Torella R, Pryde DC, Glen R, Bender A, Hošek P, Spiwok V, Mervin LH, Barrett I, Firth M, Murray DC, McWilliams L, Cao Q, Engkvist O, Warszycki D, Śmieja M, Bojarski AJ, Aniceto N, Freitas A, Ghafourian T, Herrmann G, Eigner-Pitto V, Naß A, Kurczab R, Bojarski AJ, Lange A, Günther MB, Hennig S, Büttner FM, Schall C, Sievers-Engler A, Ansideri F, Koch P, Stehle T, Laufer S, Böckler FM, Zdrazil B, Montanari F, Ecker GF, Grebner C, Hogner A, Ulander J, Edman K, Guallar V, Tyrchan C, Ulander J, Tyrchan C, Klute W, Bergström F, Kramer C, Nguyen QD, Frach R, Kibies P, Strohfeldt S, Böttcher S, Pongratz T, Horinek D, Kast SM, Rupp B, Al-Yamori R, Lisurek M, Kühne R, Furtado F, van den Broek K, Wessjohann L, Mathea M, Baumann K, Mohamad-Zobir SZ, Fu X, Fan TP, Bender A, Kuhn MA, Sotriffer CA, Zoufir A, Li X, Mervin L, Berg E, Polokoff M, Ihlenfeldt WD, Ihlenfeldt WD, Pretzel J, Alhalabi Z, Fraczkiewicz R, Waldman M, Clark RD, Shaikh N, Garg P, Kos A, Himmler HJ, Sandmann A, Jardin C, Sticht H, Steinbrecher TB, Dahlgren M, Cappel D, Lin T, Wang L, Krilov G, Abel R, Friesner R, Sherman W, Pöhner IA, Panecka J, Wade RC, Bietz S, Schomburg KT, Hilbig M, Rarey M, Jäger C, Wieczorek V, Westerhoff LM, Borbulevych OY, Demuth HU, Buchholz M, Schmidt D, Rickmeyer T, Krotzky T, Kolb P, Mittal S, Sánchez-García E, Nogueira MS, Oliveira TB, da Costa FB, Schmidt TJ.

J Cheminform. 2016 Apr 26;8(Suppl 1):18. doi: 10.1186/s13321-016-0119-5. No abstract available.

17.

Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.

Wagner L, Björkqvist M, Lundh SH, Wolf R, Börgel A, Schlenzig D, Ludwig HH, Rahfeld JU, Leavitt B, Demuth HU, Petersén Å, von Hörsten S.

J Neurochem. 2016 Jun;137(5):820-37. doi: 10.1111/jnc.13624.

18.

Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation.

Wagner L, Kaestner F, Wolf R, Stiller H, Heiser U, Manhart S, Hoffmann T, Rahfeld JU, Demuth HU, Rothermundt M, von Hörsten S.

Neuropeptides. 2016 Jun;57:21-34. doi: 10.1016/j.npep.2016.02.007. Epub 2016 Feb 27.

PMID:
26988064
19.

Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified Aβ Peptides.

Wulff M, Baumann M, Thümmler A, Yadav JK, Heinrich L, Knüpfer U, Schlenzig D, Schierhorn A, Rahfeld JU, Horn U, Balbach J, Demuth HU, Fändrich M.

Angew Chem Int Ed Engl. 2016 Apr 11;55(16):5081-4. doi: 10.1002/anie.201511099. Epub 2016 Mar 11.

PMID:
26970534
20.

Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.

Kleinschmidt M, Schoenfeld R, Göttlich C, Bittner D, Metzner JE, Leplow B, Demuth HU.

J Alzheimers Dis. 2016;50(1):111-26. doi: 10.3233/JAD-143189.

PMID:
26639953
21.

Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol.

Dammers C, Gremer L, Reiß K, Klein AN, Neudecker P, Hartmann R, Sun N, Demuth HU, Schwarten M, Willbold D.

PLoS One. 2015 Nov 23;10(11):e0143647. doi: 10.1371/journal.pone.0143647. eCollection 2015.

22.

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Frost JL, Liu B, Rahfeld JU, Kleinschmidt M, O'Nuallain B, Le KX, Lues I, Caldarone BJ, Schilling S, Demuth HU, Lemere CA.

Neurobiol Aging. 2015 Dec;36(12):3187-3199. doi: 10.1016/j.neurobiolaging.2015.08.021. Epub 2015 Aug 31.

23.

Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery.

Wagner L, Wolf R, Zeitschel U, Rossner S, Petersén Å, Leavitt BR, Kästner F, Rothermundt M, Gärtner UT, Gündel D, Schlenzig D, Frerker N, Schade J, Manhart S, Rahfeld JU, Demuth HU, von Hörsten S.

J Neurochem. 2015 Dec;135(5):1019-37. doi: 10.1111/jnc.13378. Epub 2015 Nov 16.

24.

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy.

Dammers C, Gremer L, Neudecker P, Demuth HU, Schwarten M, Willbold D.

PLoS One. 2015 Oct 5;10(10):e0139710. doi: 10.1371/journal.pone.0139710. eCollection 2015.

25.

QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.

Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen KJ, Demuth HU, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D.

Sci Rep. 2015 Sep 23;5:13222. doi: 10.1038/srep13222.

26.

IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes.

Becker A, Eichentopf R, Sedlmeier R, Waniek A, Cynis H, Koch B, Stephan A, Bäuscher C, Kohlmann S, Hoffmann T, Kehlen A, Berg S, Freyse EJ, Osmand A, Plank AC, Roßner S, von Hörsten S, Graubner S, Demuth HU, Schilling S.

Biol Chem. 2016 Jan;397(1):45-55. doi: 10.1515/hsz-2015-0192.

PMID:
26351917
27.

The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.

Kee NL, Krause J, Blatch GL, Muramoto K, Sakka K, Sakka M, Naudé RJ, Wagner L, Wolf R, Rahfeld JU, Demuth HU, Mielicki WP, Frost CL.

Protein J. 2015 Oct;34(5):338-48. doi: 10.1007/s10930-015-9628-8.

PMID:
26341972
28.

Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers.

Seifert F, Demuth HU, Weichler T, Ludwig HH, Tittmann K, Schilling S.

Bioorg Chem. 2015 Jun;60:98-101. doi: 10.1016/j.bioorg.2015.04.005. Epub 2015 Apr 24.

PMID:
25981125
29.

Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.

Hartlage-Rübsamen M, Waniek A, Meissner J, Morawski M, Schilling S, Jäger C, Kleinschmidt M, Cynis H, Kehlen A, Arendt T, Demuth HU, Rossner S.

Acta Neuropathol. 2015 Apr;129(4):565-83. doi: 10.1007/s00401-015-1395-2. Epub 2015 Feb 11.

30.

Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes.

Waniek A, Hartlage-Rübsamen M, Höfling C, Kehlen A, Schilling S, Demuth HU, Roßner S.

Biochim Biophys Acta. 2015 Jan;1852(1):146-55. doi: 10.1016/j.bbadis.2014.11.011. Epub 2014 Nov 18.

31.

Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.

Cynis H, Funkelstein L, Toneff T, Mosier C, Ziegler M, Koch B, Demuth HU, Hook V.

Neurodegener Dis. 2014;14(2):85-97. doi: 10.1159/000358430. Epub 2014 Jun 18.

32.

Mouse strain and brain region-specific expression of the glutaminyl cyclases QC and isoQC.

Höfling C, Indrischek H, Höpcke T, Waniek A, Cynis H, Koch B, Schilling S, Morawski M, Demuth HU, Roßner S, Hartlage-Rübsamen M.

Int J Dev Neurosci. 2014 Aug;36:64-73. doi: 10.1016/j.ijdevneu.2014.05.008. Epub 2014 Jun 2.

PMID:
24886834
33.

A non-canonical function of eukaryotic elongation factor 1A1: regulation of interleukin-6 expression.

Schulz I, Engel C, Niestroj AJ, Kehlen A, Rahfeld JU, Kleinschmidt M, Lehmann K, Roßner S, Demuth HU.

Biochim Biophys Acta. 2014 May;1843(5):965-75. doi: 10.1016/j.bbamcr.2014.01.022. Epub 2014 Jan 31.

34.

Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death.

Lison H, Happel MF, Schneider F, Baldauf K, Kerbstat S, Seelbinder B, Schneeberg J, Zappe M, Goldschmidt J, Budinger E, Schröder UH, Ohl FW, Schilling S, Demuth HU, Scheich H, Reymann KG, Rönicke R.

Neurobiol Dis. 2014 Mar;63:62-73. doi: 10.1016/j.nbd.2013.11.014. Epub 2013 Nov 27.

PMID:
24291517
35.

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.

Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, Roßner S.

J Alzheimers Dis. 2014;39(2):385-400. doi: 10.3233/JAD-131535.

PMID:
24164736
36.

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.

Becker A, Kohlmann S, Alexandru A, Jagla W, Canneva F, Bäuscher C, Cynis H, Sedlmeier R, Graubner S, Schilling S, Demuth HU, von Hörsten S.

BMC Neurosci. 2013 Oct 1;14:108. doi: 10.1186/1471-2202-14-108.

37.

Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.

Ramsbeck D, Buchholz M, Koch B, Böhme L, Hoffmann T, Demuth HU, Heiser U.

J Med Chem. 2013 Sep 12;56(17):6613-25. doi: 10.1021/jm4001709. Epub 2013 Aug 19.

PMID:
23886302
38.

Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.

Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St George-Hyslop P, Ikezu T, Schilling S, Demuth HU, Lemere CA.

Am J Pathol. 2013 Aug;183(2):369-81. doi: 10.1016/j.ajpath.2013.05.005. Epub 2013 Jun 7.

39.

Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.

Cynis H, Kehlen A, Haegele M, Hoffmann T, Heiser U, Fujii M, Shibazaki Y, Yoneyama H, Schilling S, Demuth HU.

Int J Exp Pathol. 2013 Jun;94(3):217-25. doi: 10.1111/iep.12020. Epub 2013 Apr 8.

40.

Structure of glutaminyl cyclase from Drosophila melanogaster in space group I4.

Kolenko P, Koch B, Rahfeld JU, Schilling S, Demuth HU, Stubbs MT.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Apr 1;69(Pt 4):358-61. doi: 10.1107/S1744309113005575. Epub 2013 Mar 28.

41.

Glutaminyl cyclases as novel targets for the treatment of septic arthritis.

Hellvard A, Maresz K, Schilling S, Graubner S, Heiser U, Jonsson R, Cynis H, Demuth HU, Potempa J, Mydel P.

J Infect Dis. 2013 Mar 1;207(5):768-77. doi: 10.1093/infdis/jis729. Epub 2012 Nov 29.

42.

Role of glutaminyl cyclases in thyroid carcinomas.

Kehlen A, Haegele M, Menge K, Gans K, Immel UD, Hoang-Vu C, Klonisch T, Demuth HU.

Endocr Relat Cancer. 2013 Feb 18;20(1):79-90. doi: 10.1530/ERC-12-0053. Print 2013 Feb.

PMID:
23183267
43.

Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy.

Sun N, Hartmann R, Lecher J, Stoldt M, Funke SA, Gremer L, Ludwig HH, Demuth HU, Kleinschmidt M, Willbold D.

J Pept Sci. 2012 Nov;18(11):691-5. doi: 10.1002/psc.2456. Epub 2012 Sep 24.

PMID:
23001756
44.

Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development.

Koch B, Buchholz M, Wermann M, Heiser U, Schilling S, Demuth HU.

Chem Biol Drug Des. 2012 Dec;80(6):937-46. doi: 10.1111/cbdd.12046. Epub 2012 Oct 11.

PMID:
22967026
45.

Crystal structures of glutaminyl cyclases (QCs) from Drosophila melanogaster reveal active site conservation between insect and mammalian QCs.

Koch B, Kolenko P, Buchholz M, Carrillo DR, Parthier C, Wermann M, Rahfeld JU, Reuter G, Schilling S, Stubbs MT, Demuth HU.

Biochemistry. 2012 Sep 18;51(37):7383-92. doi: 10.1021/bi300687g. Epub 2012 Sep 5.

PMID:
22897232
46.

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS.

Nature. 2012 May 2;485(7400):651-5. doi: 10.1038/nature11060.

47.

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation.

Schlenzig D, Rönicke R, Cynis H, Ludwig HH, Scheel E, Reymann K, Saido T, Hause G, Schilling S, Demuth HU.

J Neurochem. 2012 Jun;121(5):774-84. doi: 10.1111/j.1471-4159.2012.07707.x. Epub 2012 Mar 28.

48.

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.

Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA.

Neurodegener Dis. 2012;10(1-4):265-70. doi: 10.1159/000335913. Epub 2012 Feb 16.

49.

Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA.

J Biol Chem. 2012 Mar 9;287(11):8154-62. doi: 10.1074/jbc.M111.308601. Epub 2012 Jan 20.

50.

No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease.

Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S, Wirths O.

Neurobiol Aging. 2012 Apr;33(4):833.e39-50. doi: 10.1016/j.neurobiolaging.2011.08.006. Epub 2011 Sep 22.

PMID:
21943956

Supplemental Content

Loading ...
Support Center